Law360, New York (October 12, 2009) -- Teva Pharmaceutical Industries Ltd. has struck back with patent invalidity counterclaims against rival Gilead Sciences Inc. in an infringement case involving drug treatments for HIV.
On Friday, Teva filed a second amended answer and counterclaim to the suit Gilead brought against the company in the U.S. District Court for the Southern District of New York....
